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Introduction
Now that the Human Genome and the HapMap Projects 
have  been  completed,  the  international  scientific 
community is turning its attention to the 1000 Genomes 
Project  [1],  an  international  collaboration  between 
China, Germany, the UK, and the USA. The initial goal 
was to discover most of the genetic variation that occurs 
at  a  population  frequency  greater  than  1%  by  deep 
sequencing  at  least  1,000  individuals  from  different 
worldwide populations using next-generation platforms 
and technologies. The genomes of approximately 2,000 
individuals,  from  at  least  20  different  populations 
representing Africa, Europe, East Asia, and the Americas, 
are  being  collected  and  sequenced.  The  populations 
included will each have approximately 60 to 100 samples 
sequenced. For some populations, trios (both biological 
parents and an adult child) have been collected. Many of 
the samples, including some from the children, are going 
to be densely genotyped using genome-wide arrays. The 
goal of this study design is to reconstruct the parental 
chromosomal phase using the information provided by 
the child.
Discussion
Promising  results  have  already  arisen  from  the  Pilot  1 
analysis,  which  has  been  referred  to  as  the  ‘1000 
Genomes Low Coverage Pilot’. This analysis consists of 
180  individuals  from  the  four  original  HapMap  popu-
lations sequenced at 2X to 4X coverage, meaning that an 
average number of two to four sequences are generated 
for  every  genomic  position.  In  this  initial  phase,  more 
than  9  million  new  single-nucleotide  poly  mor  phisms 
(SNPs),  many  novel  indels  (insertions/deletions),  and 
some large structural variants have been identified.
The results that arise from the completion of this project 
will lead to a great leap in our knowledge of human genetic 
variation.  At  first,  the  results  will  allow  scientists  to 
identify  population-specific  genetic  variation  at  an 
unprecedented  degree  of  resolution.  Of  the  9  million 
novel SNPs identified so far from Pilot 1 analysis alone, 
approximately 8 million are seen in only one HapMap 
population.  Most  common  variants  have  already  been 
identified; the novel variants are disproportionately rare 
and thus more likely to be observed in only one of the 
studied populations. The identification of these variants 
will  help  the  development  of  new  population-specific 
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while  minimizing  the  ascertainment  bias  that  affects 
currently  available  arrays,  especially  for  non-European 
populations. This unbiased survey of polymorphism in 
diverse  groups  will  also  help  improve  the  imputation 
methods for genetic variants that are not represented on 
current arrays.
In addition to improving the resolution of population 
genetics, the clinical implications are endless. For example, 
genome-wide  association  studies  (GWASs)  are  now 
routinely  used  to  identify  genomic  regions  associated 
with  common  human  diseases.  However,  these  studies 
rarely  identify  the  precise  causative  genes  or  sequence 
variants. The reason for this is that the human genome 
contains regions of strong linkage disequilibrium, and a 
disease-associated  locus  can  encompass  several  genes 
and  multiple  tightly  associated  polymorphisms.  In 
addition, current arrays emphasize so-called ‘tag SNPs’, 
or SNPs that are highly correlated with their local linkage 
disequilibrium structure to provide more even coverage 
across the genome. These SNPs can usually be found in 
introns  or  intergenic  regions,  not  coding  regions  or 
known  regulatory  elements  that  are  likely  to  be  func-
tional. This makes it difficult to pinpoint causal variants 
by  association  mapping  using  genotyping  arrays  alone. 
Deep  sequencing  studies  will  identify  novel  or  rare 
functional variants, thereby allowing scientists to find all 
potential  disease-causing  variants  and  genes.  However, 
the strong associations among genetic variants in a given 
genomic region will require experimental studies to be 
performed to determine which of the associated genetic 
variants are actually functionally causal. Recent work has 
shown on a small level that resequencing of candidate 
regions from GWASs can often uncover rarer variants 
with  higher  effects  and  more  direct  functional  conse-
quences in common diseases [2].
The unprecedented level of sequence information that 
will  arise  from  the  1000  Genomes  Project  will  also 
improve our knowledge of genomic configurations that 
were  shaped  by  evolutionary  processes.  For  example, 
analyses of the distribution of SNP density along chromo-
somes will inform us about chromosomal regions that are 
more  susceptible  to  selective  pressures  or  differential 
patterns as a result of the expansion of humans through-
out  different  continents.  Recent  findings  from  exonic 
resequencing  have  shown  that  patterns  of  population-
specific rare, deleterious mutations (such as those that 
cause  Mendelian  recessive  diseases)  in  coding  regions 
can be largely explained by historical processes affecting 
specific  populations  [3].  However,  understanding  how 
these  processes  occur,  which  genes  are  affected,  and 
which other populations in the future could have a higher 
prevalence of diseases caused by rare variants requires a 
large-scale resource for validation of population genetics 
methods, a resource such as the 1000 Genomes Project. 
The  samples  that  are  included  in  the  1000  Genomes 
Project do not have identifying information, phenotypes, 
or  clinical  data  available.  The  project  is  providing  a 
resource about human genetic variation that will be used 
in  many  studies  of  particular  phenotypes,  such  as 
complex diseases or drug response.
The  availability  of  full  genome  sequences  from 
worldwide samples will directly improve the accuracy of 
direct-to-consumer  genetic  ancestry  tests.  Medical 
applications,  such  as  determining  drug  efficacy  and/or 
toxicity  and  prediction  of  disease  and  prognosis,  will 
need further deep sequencing in clinical projects before 
public  benefits  from  these  new  technologies  are 
developed. The attention from the media will probably 
increase the public’s expectations of the 1000 Genomes 
Project and its potential applications. However, scientists 
should take advantage of the increased public awareness 
to highlight the importance of genetic research and to 
encourage the participation of all communities in future 
research.  Larger  follow-up  studies  will  be  needed  to 
achieve the required statistical power to establish conclu-
sions  in  datasets  that  will  include  billions  of  variables 
integrating  genomic  data  with  future  transcriptomic, 
proteomic, and epigenetic information.
The  recent  improvements  in  sequencing  technology, 
which  allow  the  sequencing  of  samples  for  the  1000 
Genomes Project, presage the forthcoming availability of 
whole  genome  sequences  at  affordable  prices.  The 
sequencing of individual genomes raises concerns about 
potential  threats  to  privacy  and  other  ethical  issues. 
Although the USA recently passed the Genetic Infor  ma-
tion Nondiscrimination Act (GINA), prohibiting genetic 
discrimination in employment and health insurance [4], 
the protection of individual rights varies from country to 
country. For example, the European Commission strongly 
recommends the prevention of discrimination as a result 
of  genetic  testing  in  insurance  and  employment  [5]. 
However,  the  EU  does  not  have  uniform  legislation 
regarding whether it is legal for insurance companies or 
employers  to  access  genetic  testing  results  or  other 
medical  records.  Rather,  the  decision  on  whether  to 
legislate the use of genetic test results has been left to the 
discretion of each individual country.
Conclusions
The information that the 1000 Genomes Project and the 
next  generation  of  deep  sequencing  platforms  will 
provide  is  unprecedented  and  will  have  important 
implications for genetics and health as we move closer 
and closer to the era of the ubiquitous personal genome 
as part of our medical record.
Despite our best intentions, history has demonstrated 
that it will be very difficult to get the genie back into the 
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scientific  and  medical  advances.  Although  there  are 
potential social costs associated with linking informative 
genetic data to individuals or populations, we believe that 
these potential costs are outweighed by the benefits in 
terms of diagnosis and research. Scientists should continue 
to use the genetic diversity that exists within humans as 
starting  points  for  further  research.  We  cannot  stall 
scientific  progress  for  fear  of  potential  misuses  of 
knowledge. Rather, we should keep rigorous safeguards in 
place to ensure that scientific advancements proceed and 
serve  to  benefit  all  humanity.  Finally,  it  is  important  to 
establish a fluent communication with the general public 
and engage participation in genetic research.
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